Peptides are the most confused corner of the aesthetics and wellness market, and 2026 made it worse rather than better. The FDA took a group of peptides including BPC-157 off its Category 2 list, and a large part of the industry read that as permission.
It is not permission. Regulatory limbo and a green light are different things, and the difference matters if you are the one administering.
How peptides get classified
Compounding from bulk drug substances runs through FDA lists:
| Category | Meaning |
|---|---|
| 503A bulks list (21 CFR 216.23) | May be used in compounding by a state-licensed pharmacy. Six substances, none of them peptides |
| Category 1 | Under evaluation. FDA does not intend to act against 503A compounding from it while it evaluates, if the interim policy’s conditions are met |
| Category 2 | Substances with significant safety risks. Not to be compounded |
| Category 3 / under review | Nominated, under evaluation, no permission granted |
| Not on any list | No pathway. Absence is not permission. |
That last row is where most peptides sit, and where most operators get it wrong. A substance not appearing on a “do not compound” list has not thereby been approved for compounding.
What actually happened with BPC-157
In September 2023 the FDA placed BPC-157 in Category 2, its list of substances that may present significant safety risks. That closed the door.
In April 2026 both nominators withdrew their nominations, and FDA removed BPC-157 from Category 2 by April 22, 2026. The Pharmacy Compounding Advisory Committee discussed it on July 23, 2026. FDA’s own briefing recommended against adding it to the 503A bulks list, and as of September 2026 FDA had not posted minutes or started rulemaking.
Here is the part the marketing skipped: removal from Category 2 is not the same as addition to the list of substances you may compound. Coming off the “do not” list without being placed on the “may” list leaves a substance in limbo, and listing decisions run through proposed and final rulemaking, which has not started.
A committee vote is advice to the agency. It is not a rule. FDA’s guidance also says a withdrawn nomination reflects no FDA determination, so the April removal says nothing about safety. Current status for BPC-157 and eleven other compounds is on our peptide status tracker.
What that means for a practice today
If you are dispensing or administering a peptide that has no completed pathway, you are operating outside the protection that sections 503A and 503B provide. The seller’s confidence does not transfer to you. The practice that administered it carries its own exposure.
Three questions worth asking about any peptide on your menu:
- Is this substance on the 503A bulks list, or has rulemaking completed placing it there?
- If a pharmacy is supplying it, under what specific authority?
- Is the active ingredient pharmaceutical grade, with documentation, or is it labeled for research use?
“Research use only” is not a workaround
A significant share of peptide product reaching clinics is sold as research material. That labeling states the contents are not intended for human administration, and research-grade active ingredients are not permitted in human drugs.
Buying it through a clinic account rather than a consumer website does not change what it is.
The marketing problem sitting on top of it
Even where a peptide can lawfully be compounded, the claims made about it usually cannot be substantiated. Healing, recovery, longevity and performance claims are exactly the language that draws regulatory attention, and compounded preparations are not FDA-approved products regardless of how they are described.
If your website makes a therapeutic claim you could not defend with evidence, the compounding question is not your only problem.
How to hold a defensible position
- Maintain a written formulary and know the status of every item on it.
- Get the supplying pharmacy’s basis in writing, not over the phone.
- Re-check status on a schedule. This area moves, in both directions.
- Keep marketing claims inside what the evidence supports.
- Be willing to remove an item. “We stopped offering that” is a much better answer than the alternative.
Where MDside sits
We maintain the formulary for the practices we support, confirm the supplying pharmacy’s authority rather than assuming it, and update protocols as listings change. Where a substance has no completed pathway, our providers do not prescribe it, including when a competitor down the road is advertising it.
See what is included, or read what “FDA approved” actually means.
Two questions follow from this and are worth taking separately: what the courts have actually decided, covered in peptides in court, and what a lawful peptide business can be built on at all, in the five lawful shapes.
Related reading
Frequently asked questions
Is BPC-157 legal to compound now?
No. It left Category 2 in April 2026 because the nominators withdrew, which puts it in no category and outside FDA’s interim policy. FDA’s July 2026 briefing recommended against listing it, and no rulemaking has started. See the BPC-157 status page.
If a peptide is not on any FDA list, can I use it?
No. Absence from a prohibited list is not permission. Compounding pathways work by inclusion, not by omission.
My pharmacy says it is fine. Is that enough?
No. Ask for the specific authority in writing. The practice administering the product carries exposure independently of the supplier.
What about peptides sold for research use?
That labeling indicates the material is not intended for human administration, and research-grade ingredients are not permitted in human drugs.
How often does this change?
Frequently, and in both directions. Treat any peptide status as a point-in-time answer and re-verify on a schedule.
General information about compounding regulation, not legal or clinical advice. Peptide listing status is actively changing. Verify current FDA status directly and confirm with healthcare counsel and your pharmacy before acting.